Pharmaceuticals

Indivior Stock (INDV): Strong Earnings Boost Investor Confidence

Indivior exceeded Q2 2025 expectations, raising full-year forecasts, driven by strong Sublocade demand, boosting stock by ~21%.

CVS Health Stock (CVS): Strong Q2 Performance and Future Outlook

CVS Health showed strong Q2 2025 results, boosting EPS guidance and share price, driven by Aetna and pharmacy growth.

Biogen Stock (BIIB): Strong Q2 Performance Fuels Growth

Biogen's Q2 2025 shows strong growth with new drugs boosting revenue and EPS, despite challenges in legacy MS treatments.

Exact Sciences Stock (EXAS): Cologuard Plus Expansion Benefits

Exact Sciences broadens partnership with Humana, offering Cologuard Plus for 5.8 million members, enhancing access and driving growth.

ProKidney Stock (PROK): Is the Hype Justified?

ProKidney's stock soared after promising Phase 2 trial results, highlighting the potential but also the risks in biotech investments.

Recursion Pharmaceuticals Stock (RXRX): AI Breakthrough for Drug Development

Recursion Pharmaceuticals partners with MIT for Boltz-2, an AI model predicting binding affinity at unprecedented speed and accuracy.

Taysha Gene Therapies Stock (TSHA): Innovative Gene Therapy Focus

Taysha Gene Therapies (NASDAQ: TSHA) is gaining investor attention with TSHA-102, its lead Rett syndrome gene therapy. Learn why this biotech stock is a rising contender in the CNS space.

Cidara Therapeutics Stock (CDTX): A Notable Contender in Antivirals

Cidara Therapeutics aims to innovate antivirals with CD388, targeting flu prevention. Positive trial results may boost stock.

Vigil Neuroscience Stock (VIGL): Buyout Boosts Valuation

Vigil Neuroscience's stock soared after Sanofi agreed to buy it for $8.00 per share, tied to the potential success of its Alzheimer’s drug VG-3927.

Capricor Stock (CAPR) Launch Hype Builds on Potential Breakthrough Therapy

Capricor Therapeutics (CAPR) stock climbs as FDA decision nears for its Duchenne therapy, with peak sales forecast at $3.3B by 2038.

Geron Corp Stock (GERN): Demand Recovery on the Rise

Geron Corporation's stock (GERN) is gaining attention due to its promising biotech advancements, particularly with its lead drug, Rytelo.

CytomX Therapeutics Stock (CTMX): Momentum from Promising Trials

CytomX Therapeutics stock surges 280% on promising cancer data and a $93.4 million stock offering, bolstering its financial future.

Iovance Biotherapeutics Stock (IOVA): Navigating Turbulent Times

Iovance shares plunged on weak Q1 results and production issues, then bounced 10% as investors reassessed. Legal risks and volatility remain high.

Roche (RHHBY): Significant U.S. Investment to Enhance Manufacturing and Innovation

Roche plans to invest $50 billion in the U.S., creating over 12,000 jobs and expanding its manufacturing and R&D capabilities.

Eli Lilly and Co (NYSE:LLY): Promising Breakthrough in Weight-Loss Treatments

Eli Lilly's orforglipron shows promise as a weight-loss pill, boosting shares by 12% and marking a major milestone in diabetes treatment.